ClinicalTrials.gg

Program

benralizumab

Also written as “Benralizumab”, “Benralizumab 100 mg” and “KHK4563”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Churg-Strauss Syndrome · Nasal Polyps · Hypereosinophilic Syndrome, led by 2 companies.

Furthest: phase 4, since Apr 10, 201948 company-led studies, 5 open or runningNext primary completion: Dec 23, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca465 open or runningphase 4since Apr 10, 2019Aug 6, 2007Dec 23, 2026phase 3 · NCT05692180
Kyowa Kirin20 open or runningphase 2since Aug 7, 2011Aug 7, 2011none ahead

Also a collaborator on its studies: parexel, iqvia-pty-ltd, covance and ppd-development-lp.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 32 studies since Aug 6, 2007.

  1. Oct 23, 2019Phase 3 study in Nasal PolypsAstraZeneca · NCT04157335 · 295 enrolled · United States, Argentina, Australia and more
  2. Nov 15, 20192 phase 3 studiesAstraZeneca · NCT04305405, NCT04191304
  3. Aug 18, 2020Phase 3 study in Eosinophilic EsophagitisAstraZeneca · NCT04543409 · 211 enrolled · United States, Canada, France and more
  4. Sep 1, 20202 phase 2 studiesAstraZeneca · NCT04605094, NCT04612725
  5. Oct 12, 2020Phase 3 study in Pemphigoid, BullousAstraZeneca · NCT04612790 · 67 enrolled · United States, Australia, Bulgaria and more
  6. Jun 23, 2021Phase 3 study in Non-cystic Fibrosis BronchiectasisAstraZeneca · NCT05006573 · 100 enrolled · United States, Argentina, Australia and more
  7. Aug 6, 2021Phase 3 study in Eosinophilic enteropathyAstraZeneca · NCT05251909 · 12 enrolled · United States, Brazil, Italy and more
  8. Nov 9, 2021Phase 4 study in In Adult Patients of Severe Asthma With Eosinophilic Phenotype in IndiaAstraZeneca · NCT05384938 · 139 enrolled · India
  9. Apr 27, 2022Phase 4 study in AsthmaAstraZeneca · NCT05552508 · 45 enrolled · United States, Australia, Belgium and more
  10. Jan 11, 2023Phase 3 study in AsthmaAstraZeneca · NCT05692180 · 94 enrolled · United States, Argentina, France and more
  11. Feb 1, 2024Phase 3 study in Pulmonary EosinophiliaAstraZeneca · NCT06465485 · 504 enrolled · China
  12. Jul 17, 2024Phase 3 study in Churg-Strauss SyndromeAstraZeneca · NCT06512883 · 14 planned · United States, Brazil, Canada and more
  13. Nov 20, 2024Phase 3 study in Pulmonary EosinophiliaAstraZeneca · NCT06750289 · 130 enrolled · United States, Bulgaria, Canada and more
  14. Feb 17, 2026Phase 3 study in AsthmaAstraZeneca · NCT07444567 · 230 planned · United States, Argentina, Austria and more

Ahead

  1. Dec 23, 2026Primary completion: phase 3 study in AsthmaAstraZeneca · NCT05692180
  2. Feb 20, 2028Primary completion: phase 3 study in Churg-Strauss SyndromeAstraZeneca · NCT06512883
  3. Dec 27, 2029Primary completion: phase 3 study in AsthmaAstraZeneca · NCT07444567

TargetBeta

IL5RA →read by rule
“Interleukin-5 receptor subunit alpha inhibitor”ChEMBL 37, by rule

Studies

All 48 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07444567Asthma · United States, Argentina, Austria and more3RecruitingAstraZenecaDec 27, 2029230
NCT06750289Pulmonary Eosinophilia · United States, Bulgaria, Canada and more3CompletedAstraZenecaSep 21, 2026130
NCT06512883Churg-Strauss Syndrome · United States, Brazil, Canada and more3RecruitingAstraZenecaFeb 20, 202814
NCT06465485Pulmonary Eosinophilia · China3CompletedAstraZenecaMay 13, 2026504
NCT05692180Asthma · United States, Argentina, France and more3Active, not recruitingAstraZenecaDec 23, 202694
NCT05552508Asthma · United States, Australia, Belgium and more4CompletedAstraZenecaJul 19, 202445
NCT05384938In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India · India4CompletedAstraZenecaJul 1, 2023139
NCT05251909Eosinophilic enteropathy · United States, Brazil, Italy and more3TerminatedAstraZenecaFeb 13, 202412
NCT05006573Non-cystic Fibrosis Bronchiectasis · United States, Argentina, Australia and more3TerminatedAstraZenecaApr 16, 2024100
NCT04612790Pemphigoid, Bullous · United States, Australia, Bulgaria and more3TerminatedAstraZenecaOct 26, 202367
NCT04612725Chronic Urticaria · United States, Bulgaria, Germany and more2TerminatedAstraZenecaOct 13, 2022159
NCT04605094Dermatitis, Atopic · United States, Australia, Bulgaria and more2TerminatedAstraZenecaApr 25, 2022194
NCT04543409Eosinophilic Esophagitis · United States, Canada, France and more3TerminatedAstraZenecaSep 19, 2022211
NCT04191304Hypereosinophilic Syndrome · United States, Argentina, Austria and more3Active, not recruitingAstraZenecaMay 7, 2025134
NCT04305405Asthma · United States, Japan3CompletedAstraZenecaSep 12, 202230
NCT04157335Nasal Polyps · United States, Argentina, Australia and more3TerminatedAstraZenecaAug 6, 2024295
NCT04159519Asthma · France, Germany, Italy and more4CompletedAstraZenecaJan 31, 2023170
NCT04157348Churg-Strauss Syndrome · United States, Belgium, Canada and more3Active, not recruitingAstraZenecaAug 10, 2023140
NCT04053634Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more3CompletedAstraZenecaJul 28, 2025689
NCT03953300Asthma · United States, Canada, Denmark and more4CompletedAstraZenecaOct 20, 202675
NCT03928262Healthy Subjects · Hong Kong1CompletedAstraZenecaAug 12, 201936
NCT03557307Asthma · United States, Argentina, Belgium and more3CompletedAstraZenecaApr 16, 2021598
NCT03401229Nasal Polyps · United States, Austria, Belgium and more3CompletedAstraZenecaJul 31, 2020413
NCT03170271Asthma · United States, Austria, Belgium and more3CompletedAstraZenecaSep 25, 2019660
NCT03186209Asthma · China, Korea, Republic of, Philippines and more3CompletedAstraZenecaJan 30, 2023695
NCT02968914Asthma · Germany1CompletedAstraZenecaJul 13, 2017180
NCT02918071Asthma · United States, Canada3CompletedAstraZenecaAug 21, 2017121
NCT02869438Asthma · United States, Chile, Germany and more3CompletedAstraZenecaAug 1, 2018233
NCT02821416Asthma · Canada3CompletedAstraZenecaOct 22, 201946
NCT02814643Asthma · United States3CompletedAstraZenecaJan 24, 2017103
NCT02808819Asthma · United States, Argentina, Australia and more3CompletedAstraZenecaJun 18, 2020447
NCT02772419Eosinophilic Chronic Rhinosinusitis · Japan2CompletedKyowa KirinMar 27, 201763
NCT02417961Asthma · United States, Canada3CompletedAstraZenecaMar 14, 2016162
NCT02322775Asthma · United States, Canada, Germany and more3CompletedAstraZenecaOct 7, 2015211
NCT02258542Asthma · United States, Argentina, Australia and more3CompletedAstraZenecaOct 18, 20172,133
NCT02155660Lung Diseases, Obstructive · United States, Argentina, Australia and more3CompletedAstraZenecaApr 9, 20182,255
NCT02138916Lung Diseases, Obstructive · United States, Austria, Canada and more3CompletedAstraZenecaApr 10, 20181,656
NCT02075255Asthma · United States, Argentina, Bulgaria and more3CompletedAstraZenecaAug 8, 2016220
NCT01947946Asthma · United States, Argentina, Brazil and more3TerminatedAstraZenecaJul 201413
NCT01928771Asthma · United States, Australia, Brazil and more3CompletedAstraZenecaApr 5, 20162,681
NCT01914757Asthma · United States, Argentina, Canada and more3CompletedAstraZenecaMar 20162,508
NCT01412736Uncontrolled and Suspected Eosinophilic Asthma · Japan, Korea, Republic of2CompletedKyowa KirinJul 2013106
NCT01238861Asthma · United States, Argentina, Brazil and more2CompletedAstraZenecaMar 2013964
NCT01227278Pulmonary Disease, Chronic Obstructive · United States, Canada, Denmark and more2CompletedAstraZenecaJan 2013421
NCT00783289Asthma · United States2CompletedAstraZenecaNov 17, 200935
NCT00768079Asthma · United States, Canada2CompletedAstraZenecaDec 17, 2010110
NCT00659659Asthma · United States, Canada1CompletedAstraZenecaJan 201127
NCT00512486Asthma · United States1CompletedAstraZenecaSep 200842

How it is read

Names in the registry

  • “Benralizumab”, 38 entries
  • “benralizumab”, 3 entries
  • “Benralizumab 100 mg”, 3 entries
  • “KHK4563”, 3 entries
  • “MEDI-563”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.